griseofulvin and Pain

A total of 57 herpes zoster patients (28 men and 28 women) were randomly assigned to one of the following four treatments: griseofulvin, 125 mg four times daily; methisoprinol, 1 g four times daily; griseofulvin plus methisoprinol (dosage schedules as above); placebo, four times daily. Griseofulvin had no effect at all, methisoprinol both significantly accelerated drying of vesicles and reduced pain, and the combination of griseofulvin and methisoprinol turned out to be significantly more effective in reducing pain than methisoprinol alone. The present results suggest a new effective treatment for herpes zoster disease.

Topics: Aged; Drug Interactions; Drug Therapy, Combination; Female; Griseofulvin; Herpes Zoster; Humans; Inosine; Inosine Pranobex; Male; Middle Aged; Pain

Topics: Adolescent; Adult; Aged; Child; Clinical Trials as Topic; Evaluation Studies as Topic; Female; Griseofulvin; Headache; Humans; Immunosuppressive Agents; Menstruation Disturbances; Middle Aged; Pain; Scleroderma, Systemic; Time Factors; Vertigo

Lichen planus is one of the most common dermatologic diseases involving the skin and oral mucous membranes. It may occur anywhere in the oral cavity. Erosive lichen planus has been reported to undergo malignant transformation, making definitive diagnosis, treatment, and followup essential. The purpose of this study was to establish the effectiveness of griseofulvin therapy on erosive lichen planus and to provide an alternative to steroid therapy. The results of this study revealed that griseofulvin had little or no effect on pain, pigmentation, or disappearance of erosive lichen planus and did not protect the patient from further recurrences.

Topics: Adult; Aged; Female; Griseofulvin; Humans; Lichen Planus; Male; Middle Aged; Mouth Diseases; Pain; Recurrence

Topics: Biomedical Research; Dermatomycoses; Drug Therapy; Epidermis; Griseofulvin; Pain; Pharmacology; Skin